tbuckley/cabot-search huggingface dataset:
P1.09-33 Validity of Non-Small Cell Lung Cancer Not Otherwise Specified to Use Immunohistochemistry on Treatment Outcome
Authors: T. Ota, K. Kirita, H. Udagawa, S. Umemura, S. Matsumoto, K. Yoh, S. Niho, G. Ishii, K. Goto
Journal: Journal of Thoracic Oncology (2018)
P1.13-27 A Randomized Study of Concurrent vs Sequential Alternating EGFR-TKIs and Chemotherapy for Advanced NSCLC with EGFR Mutations
Authors: H. Yong, L. Hui, L. Fang, L. Dong, X. Ling, W. Qiang, X. Peng, H. Hua, Y. Yang, G. Ping, K. Cui, W. Wu, C. Yu, L. Huo, X. Qiang, S. Xi, C. Jin
Journal: Journal of Thoracic Oncology (2018)
Non-viral, Tumor-free Induction of Transient Cell Reprogramming in Mouse Skeletal Muscle to Enhance Tissue Regeneration
Authors: Irene de Lázaro, Acelya Yilmazer, Yein Nam, Sara Qubisi, Fazilah Maizatul Abdul Razak, Hans Degens, Giulio Cossu, Kostas Kostarelos
Journal: Molecular Therapy (2018)

Overexpression of Oct3/4, Klf4, Sox2, and c-Myc (OKSM) transcription factors can de-differentiate adult cells in vivo. While sustained OKSM expression triggers tumorigenesis through uncontrolled proliferation of toti- and pluripotent cells, transient reprogramming induces pluripotency-like features and proliferation only temporarily, without teratomas. We sought to transiently reprogram cells within mouse skeletal muscle with a localized injection of plasmid DNA encoding OKSM (pOKSM), and we hypothesized that the generation of proliferative intermediates would enhance tissue regeneration after injury. Intramuscular pOKSM administration rapidly upregulated pluripotency (Nanog, Ecat1, and Rex1) and early myogenesis genes (Pax3) in the healthy gastrocnemius of various strains. Mononucleated cells expressing such markers appeared in clusters among myofibers, proliferated only transiently, and did not lead to dysplasia or tumorigenesis for at least 120 days. Nanog was also upregulated in the gastrocnemius when pOKSM was administered 7 days after surgically sectioning its medial head. Enhanced tissue regeneration after reprogramming was manifested by the accelerated appearance of centronucleated myofibers and reduced fibrosis. These results suggest that transient in vivo reprogramming could develop into a novel strategy toward the acceleration of tissue regeneration after injury, based on the induction of transiently proliferative, pluripotent-like cells in situ. Further research to achieve clinically meaningful functional regeneration is warranted.
Steroids and severe pneumonia. Ready for the winter? Discussion on “Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study”
Authors: Gennaro De Pascale, G. Bello, A. M. Dell’Anna, L. Montini, M. Antonelli, Gerard Moreno, Alejandro Rodriguez, Ignacio Martin-Loeches
Journal: Intensive Care Medicine (2018)
A randomized phase II trial of adjuvant chemotherapy with gemcitabine versus S-1 after major hepatectomy for biliary tract cancer: Kansai Hepato-Biliary Oncology Group (KHBO1208)
Authors: H. Terajima, S. Kobayashi, H. Nagano, A. Tomokuni, K. Gotoh, D. Sakai, E. Hatano, S. Seo, Y. Uchida, T. Ajiki, H. Satake, K. Kamei, T. Tohyama, T. Hirose, I. Ikai, S. Morita, T. Ioka
Journal: Annals of Oncology (2018)
Pathologic assessment following neoadjuvant immunotherapy or chemotherapy demonstrates similar patterns in non-small cell lung cancer (NSCLC)
Authors: A. Weissferdt, B. Sepesi, A. Pataer, N. Kalhor, C.A. Moran, W.N. William, X. Le, B. Glisson, F. Skoulidis, G. Blumenschein, J. Zhang, M. Altan, D. Rice, R. Mehran, J.J. Lee, A. Vaporciyan, D.L. Gibbons, S.G. Swisher, J.V. Heymach, T. Cascone
Journal: Annals of Oncology (2018)
P1.04-09 Immunomodulatory Effects of Afatinib and Pembrolizumab in EGFR-Mutant NSCLC with Progression on Prior EGFR-TKI
Authors: J. Riess, K. Kelly, K. Schalper, M. Shimoda, S. Lim, A. Monjazeb, K. Danenberg, E. Moore, L. Beckett, P. Mack, E. Maverakis, D. Gandara
Journal: Journal of Thoracic Oncology (2018)
Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis
Authors: A. Bardia, S. Campos-Gomez, S.A. Hurvitz, Y.-S. Lu, S.-A. Im, F. Franke, L. Chow, P. Wheatley-Price, F. Melo Cruz, J. Alam, O. Kong, I. Diaz-Padilla, M. Miller, D. Tripathy
Journal: Annals of Oncology (2018)
P3.04-21 Antibiotics Attenuate the Clinical Benefit of Anti-PD-(L)1 Immunotherapies in Chinese Patients with Advanced Non-Small Cell Lung Cancer
Authors: S. Zhao, Y. Jia, T. Jiang, X. Li, W. Li, G. Gao, C. Zhao, Y. He, X. Chen, C. Su, S. Ren, C. Zhou
Journal: Journal of Thoracic Oncology (2018)
OA05.07 IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC
Authors: V. Papadimitrakopoulou, M. Cobo, R. Bordoni, P. Dubray-Longeras, Z. Szalai, G. Ursol, S. Novello, F. Orlandi, S. Ball, J. Goldschmidt, R. Sanborn, T. Hoang, D. Mendus, Y. Deng, M. Kowanetz, X. Wen, W. Lin, A. Sandler, M. Nishio
Journal: Journal of Thoracic Oncology (2018)
Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog® IMA101) in patients with relapsed and/or refractory solid cancers
Authors: A.-M. Tsimberidou, H. Ma, C. Stewart, O. Schoor, D. Maurer, R. Mendrzyk, A. Satelli, J. Fritsche, G. Stephens, A. Mohamed, P. Hwu, C. Yee, C. Reinhardt, T. Weinschenk, K. Gharpure, A. Stungis, D.J. Vining, H. Singh, S. Walter, B.S. Andersson
Journal: Annals of Oncology (2018)
The protective effect of cheese consumption at 18 months on allergic diseases in the first 6 years
Authors: Sophie Nicklaus, Amandine Divaret‐Chauveau, Marie‐Laure Chardon, Caroline Roduit, Vincent Kaulek, Eléa Ksiazek, Marie‐Laure Dalphin, Anne M. Karvonen, Pirkka Kirjavainen, Juha Pekkanen, Roger Lauener, Elisabeth Schmausser‐Hechfellner, Harald Renz, Charlotte Braun‐Fahrländer, Josef Riedler, Dominique A. Vuitton, Erika Von Mutius, Jean‐Charles Dalphin
Journal: Allergy (2018)

The effect of exposure to microorganisms on allergic diseases has been well studied. The protective effect of early food diversity against allergic diseases was previously shown in the PASTURE cohort study. The consumption of cheese, a food potentially rich in microbial diversity, deserves further examination. We aimed to evaluate whether cheese consumption is associated with allergic diseases.In the PASTURE study (birth cohort in 5 European countries), data on feeding practices, environmental factors, and allergic diseases were collected by questionnaires from birth to 6 years (N = 931). Cheese consumption at 18 months of age was quantified in terms of frequency and diversity (ie, number of consumed types among 6 types: hard pressed, semipressed, soft, blue, fresh cheese, and cheese from the farm). Multiple logistic regressions were performed to evaluate the effect of cheese consumption on atopic dermatitis (AD), food allergy (FA), allergic rhinitis, asthma, and atopic sensitization at 6 years after adjustment for confounders of atopy.Cheese consumption (vs. nonconsumption) had a significant protective effect on AD (OR = 0.51 [0.29-0.90], P = 0.02) and FA (OR = 0.32, [0.15-0.71], P = 0.004), but no effect on atopic sensitization, allergic rhinitis, and asthma at 6 years. This effect on AD and FA may be related to the diversity of consumed cheeses (OR = 0.64 [0.48-0.85] per cheese type, P = 0.002; OR = 0.55 [0.33-0.92], P = 0.02, respectively).Although reverse causality cannot totally be ruled out, cheese diversity at 18 months had a protective effect against AD and FA at 6 years in addition to the protective effect of diversity of other foods.
TROPHIMMUN, a 2 cohort phase II trial of the anti-PD-L1 monoclonal antibody avelumab in chemo-resistant gestational trophoblastic neoplasia (GTN) patients: Preliminary outcomes in cohort A
Authors: B.M. You, P.A. Bolze, J.-P. Lotz, J. Massardier, L. Gladieff, T. Hajri, D. Maucort-Boulch, S. Bin, A. Roux, P. Rousset, G. Freyer, F. Golfier
Journal: Annals of Oncology (2018)
Correlation between clinic-pathological features, MSI, PD-L1 and survival in resectable gastric cancer: Looking for prognostic biomarkers
Authors: M. Ratti, N. Valeri, J.C. Hahne, A. Lampis, M. Ghidini, G. Tomasello, G. Tanzi, L. Toppo, C. Pizzo, B. Donida, C. Senti, M. Salati, M. Trombatore, M. Fassan, R. Passalacqua
Journal: Annals of Oncology (2018)
PAPD5/7 Are Host Factors That Are Required for Hepatitis B Virus RNA Stabilization
Authors: Henrik Mueller, Anaïs Lopez, Philipp Tropberger, Steffen Wildum, Josephine Schmaler, Lykke Pedersen, Xingchun Han, Yongguang Wang, Søren Ottosen, Song Yang, John A.T. Young, Hassan Javanbakht
Journal: Hepatology (2018)

RG7834 is a potent, orally bioavailable small‐molecule inhibitor of hepatitis B virus (HBV) gene expression that belongs to the dihydroquinolizinone (DHQ) chemical class and uniquely blocks production of both viral DNA and antigens. In this study, we used DHQ compounds as tools in a compound‐based adaptation version of the yeast three‐hybrid screen to identify the cognate cellular protein targets, the non‐canonical poly(A) RNA polymerase associated domain containing proteins 5 and 7 (PAPD5 and PAPD7). Interaction with RG7834 was mapped to the catalytic domains of the two cellular enzymes. The role of PAPD5 and PAPD7 in HBV replication was confirmed by oligonucleotide‐mediated knockdown studies that phenocopied the result seen with RG7834‐treated HBV‐infected hepatocytes. The greatest effect on HBV gene expression was seen when PAPD5 and PAPD7 mRNAs were simultaneously knocked down, suggesting that the two cellular proteins play a redundant role in maintaining HBV mRNA levels. In addition, as seen previously with RG7834 treatment, PAPD5 and PAPD7 knockdown led to destabilization and degradation of HBV mRNA without impacting production of viral RNA transcripts. Conclusion : We identify PAPD5 and PAPD7 as cellular host factors required for HBV RNA stabilization and as therapeutic targets for the HBV cure.
P1.12-19 Clinico-Pathological Characteristics and Treatment Outcome in Small Cell Lung Cancer: A Single Institutional Experience
Authors: S. Ganguly, B. Biswas, J. Ghosh, R. Shrimali, S. Sen, S. Mukhopadhyay, G. Mukherjee, D. Midha, D. Dabkara, A. Basu, M. Chatterjee, A. Hassan, S. Das
Journal: Journal of Thoracic Oncology (2018)
Abstract 16426: Vasculature-Designed 3-Dimensional Artificial Cardiac Tissue Derived From Human Induced Pluripotent Stem Cells: An Engineered Cardiac Graft to Enhance Vascular Network Formation With the Scarred Myocardium in Rat
Authors: Junya Yokoyama, Shigeru Miyagawa, Satsuki Fukushima, Yasushi Takamura, Yoshiaki Shima, Mitsuru Akashi, Koichi Toda, Takayoshi Ueno, Toru Kuratani, Yoshiki Sawa
Journal: Circulation (2016)

Introduction: While transplantation of artificial cardiac tissue is a promising strategy to treat advanced chronic myocardial infarction (MI) heart, ischemia in the graft is a concern as a limiting factor of its therapeutic potential. We recently developed a new technology by which human induced pluripotent stem cell-derived cardiac myocytes (iPSC-CMs) formed 3-dimensional (D) artificial cardiac tissue including microvascular network in vitro. We hypothesized that transplanted artificial cardiac tissue may be integrated into the MI heart, leading to functional recovery. Methods: hiPSC-CMs, endothelial cells and cardiac fibroblasts of human origin were coated with fibronectin and gelatin, and then incubated in cell culture insert to reconstruct vascularized 3D cardiac tissue in vitro, which was epicardially transplanted into the scarred myocardium of nude rat that was subjected to left coronary artery ligation X weeks prior to the treatment, or sham operation was performed (n=10 each). Results: The 3D-card...
Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection
Authors: Shi Liu, Bin Zhou, Juan D. Valdes, Jian Sun, Haitao Guo
Journal: Hepatology (2018)

Chronic hepatitis B infection is one of the major etiological causes of liver failure, cirrhosis, and hepatocellular carcinoma (HCC) worldwide. This condition cannot be completely cured by currently available drugs due to the persistent existence of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA), the bona fide transcription template for HBV RNAs, in infected hepatocytes. Because quantifying cccDNA per se requires an invasive procedure, serum biomarkers reflecting intrahepatic cccDNA activity are warranted. Recently, a growing body of research suggests that the circulating HBV RNA may serve as a serum biomarker for HBV infection, treatment, and prognosis. In order to delineate the molecular and clinical characteristics of serum HBV RNA, we systematically reviewed the available literature on serum HBV RNA dating back to the early 1990s. In this review, we summarize the reported serum HBV RNA quantification methods and discuss the potential HBV RNA species in patient serum. We also compare the reported correlations of serum HBV RNA with other serological markers, including HBV DNA, hepatitis B surface antigen, e antigen, and core‐related antigen, as well as their correlations with intrahepatic cccDNA, to assess their potential in clinical applications. Future directions for serum HBV RNA research are also discussed.
P1.13-40 Rapid, Robust and Durable Responses to Larotrectinib in Patients with TRK Fusion Non-Small Cell Lung Cancer
Authors: A. Farago, S. Kummar, S. Ibabekci, S. Corsi-Travali, S. Cruickshank, M. Cox, N. Ku, A. Drilon
Journal: Journal of Thoracic Oncology (2018)
Abstract P174: Early Onset Parental Hypertension is Associated With Hypertension Status of Their Offspring
Authors: Yongwoo Jeon, Hyeon Chang Kim, Hyungseon Yeom, Dahye Jeon, Jee-Seon Shim, Kay-Tee Khaw, Il Suh
Journal: Circulation (2018)

Background: Family history is a important risk factor for hypertension (HT), however impacts of parental early onset versus late onset on offspring’s HT has not been explored yet in Asian countries. Methods and Results: We analyzed 1,524 participants from two Korean prospective cohorts in cross-sectional design. Early onset was defined as onset before age of 55 and participants were categorized according to parental hypertension(PH) status; “No PH”, “late onset PH” and “early onset PH”. Logistic regression was conducted to compare risks of HT on parental, maternal and paternal HT status. Participants’ HT onset age was compared using least-square means. Overall prevalence of HT was 25.7% (392/1,524) and that of “early onset PH” group was 33.7% (98/291). This group conferred an OR of 3.83 (95% CI, 2.67-5.54) for HT. The onset age of HT was earliest in this group (48.2 years; 95% CI, 47.3-49.2). Conclusions: Early onset HT in parents was associated with high HT prevalence in offspring and also with their onset age. Therefore, for applying early prevention and intervention to the high risk population, it would be beneficial to identify whether individuals had early onset PH.
MA12.09 Preclinical Investigations of Folate Receptor Targeted Nanoparticles for Photodynamic Therapy of Malignant Pleural Mesothelioma
Authors: T. Kato, C. Jin, H. Ujiie, K. Fujino, D. Lee, H. Wada, H. Hu, L. Wu, R. Weersink, J. Chen, H. Kanno, Y. Hatanaka, K. Hatanaka, Y. Matsuno, M. De Perrot, B. Wilson, G. Zheng, K. Yasufuku
Journal: Journal of Thoracic Oncology (2018)
Photodynamic therapy for actinic keratosis of the forehead and scalp: a randomized, controlled, phase<scp>II</scp>clinical study evaluating the noninferiority of a new protocol involving irradiation with a light‐emitting, fabric‐based device (the Flexitheralight protocol) compared with the conventional protocol involving irradiation with the Aktilite<scp>CL</scp>128 lamp
Authors: C. Vicentini, A.S. Vignion‐Dewalle, E. Thecua, F. Lecomte, C. Maire, P. Deleporte, H. Béhal, D. Kerob, A. Duhamel, S. Mordon, L. Mortier
Journal: British Journal of Dermatology (2018)

Photodynamic therapy (PDT) is an effective treatment for actinic keratosis (AK), particularly for patients with large areas of field cancerization. Among the approved protocols in Europe, the most widely used requires irradiation with the Aktilite CL 128 lamp. However, pain during irradiation and the suboptimal adaptability of the lamp relative to the treatment area are two limiting factors of this protocol. To overcome these limits, a new protocol (referred to as the Flexitheralight protocol) involving irradiation with a light‐emitting, fabric‐based device was developed. This paper aims to assess the noninferiority, in terms of PDT efficacy for treating AK, of the Flexitheralight protocol compared with the conventional protocol, which requires irradiation with the Aktilite CL 128 lamp. A monocentric, randomized, controlled, phase II clinical study was performed. Twenty‐five patients with grade I–II AKs of the forehead and scalp were treated with methyl aminolaevulinate PDT in two symmetrical areas. One area was treated with the conventional protocol (n = 154 AKs), whereas the other area was treated with the Flexitheralight protocol (n = 156 AKs). The primary end‐point was the lesion complete response (CR) rate at 3 months (an absolute noninferiority margin of –10% was used). The secondary end‐points included patient‐reported pain at the end of the irradiation. At 3 months, the lesion CR rate with the Flexitheralight protocol was noninferior to that obtained with the conventional protocol (66·0% vs. 59·1%, respectively; absolute difference, 6·9%; 95% confidence interval –0·6% to 14·5%). Patient‐reported pain was significantly lower with the Flexitheralight protocol than with the conventional protocol (mean ± SD: 0·4 ± 0·6 vs. 5·0 ± 2·6; P < 0·0001). The Flexitheralight protocol is noninferior in terms of efficacy and superior in terms of tolerability to the conventional protocol for treating AKs of the forehead and scalp.
MA25.05 Characteristics and Survival of Resected Stage IV Non-Small Cell Lung Cancer (NSCLC) in the Mid-South Quality of Surgical Resection Cohort
Authors: N. Faris, Y. Lee, M. Smeltzer, M. Ray, C. Fehnel, C. Houston-Harris, O. Akinbobola, P. Ojeabulu, E. Owen, R. Eubanks, H. Dox, D. Talton, G. Valaulikar, H. Wiggins, B. Wolf, P. Levy, E. Robbins, R. Osarogiagbon
Journal: Journal of Thoracic Oncology (2018)
Palbociclib in combination with letrozole as first or later line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study
Authors: M.K. Welslau, M. Zaiss, U. Söling, M. Untch, L. Müller, D. Lüftner, J. Meiler, A. Welt, J. Sahlmann, L. Houet, E. Runkel, N.W. Marschner
Journal: Annals of Oncology (2018)
Circulating tumor DNA and RNA as an exploratory biomarker to evaluate GT0918 in a phase I/II clinical trial in mCRPC patients
Authors: M. Tan, S. Zhang, Z. Zhao, A. Wang, D. Cheung, P. Du, J. Yu, S. Jia, C. Guo, Y. Tong, K. Zhou
Journal: Annals of Oncology (2018)
P3.01-72 Pulmonary Resection in a Prone Position for Lung Cancer Invading the Spine: Two Cases Report
Authors: S. Miyauchi, J. Soh, K. Araki, A. Miura, Y. Takahashi, E. Kurihara, Y. Ogoshi, K. Shien, H. Yamamoto, S. Sugimoto, M. Yamane, S. Toyooka
Journal: Journal of Thoracic Oncology (2018)
P3.01-101 A Retrospective Study of Lung Cancer that has Progressed to Brain Metastasis Alone
Authors: K. Tsuruoka, H. Tsuji, K. Miyoshi, N. Matsunaga, T. Nakamura, Y. Tamura, M. Imanishi, S. Ikeda, Y. Fujisaka, I. Goto
Journal: Journal of Thoracic Oncology (2018)
P2.04-10 Early Monitoring of Blood Biomarkers to Predict Nivolumab Efficacy in NSCLC Patients
Authors: F. Passiglia, A. Galvano, H. Soto Parra, S. Rizzo, A. Listì, S. Mazzarisi, A. Perez, M. Castiglia, V. Calò, V. Bazan, A. Russo
Journal: Journal of Thoracic Oncology (2018)
Vall d’Hebron Institute of Oncology (VHIO) immuno-oncology prognostic index (VIO): A new tool for improved patient (pt) selection in phase I (Ph1) trials with immune checkpoint inhibitors (ICI)
Authors: C. Hierro, I. Matos, J. Martin-Liberal, M. Ochoa De Olza Amat, E. Felip, M. Costa Rivas, M. Vieito Villar, I. Brana, A. Azaro, M.C. Perez-Gago, A. Gros, J. Carles, A. Oaknin, T. Macarulla, C. Saura, N. pardo, E. Muñoz-Couselo, J. Tabernero, R. Dienstmann, E. Garralda
Journal: Annals of Oncology (2018)
Efficacy of lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: Results of the international phase II TALENT trial (GETNE 1509)
Authors: J. Capdevila, N. Fazio, C. Lopez, A. Teule, J.W. Valle, S. Tafuto, A. Custodio, N. Reed, M. Raderer, E. Grande, R. Garcia-Carbonero, P. Jimenez Fonseca, V. Alonso, L. Antonuzzo, A. Spallanzani, A. Berruti, I. Sevilla Garcia, A. La Casta, J. Hernando, T. Ibrahim
Journal: Annals of Oncology (2018)
Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): Final results from the prospective, observational CORRELATE study
Authors: J.M. O’Connor, M. Ducreux, L.N. Petersen, L. Öhler, F. Bergamo, J.-P. Metges, J.W. de Groot, J.-Y. Wang, B. García Paredes, E. Dochy, S. Fiala-Buskies, A. Cervantes, A. Falcone
Journal: Annals of Oncology (2018)
Survival update in randomized phase II trial of S-1/cisplatin (SP) or docetaxel/cisplatin (DP) with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer (NSCLC)-TORG1018
Authors: Y. Takiguchi, K. Yamada, H. Tanaka, K. Kubota, K. Kishi, T. Shimokawa, H. Saito, Y. Hosomi, T. Kato, N. Nogami, S. Igawa, T. Kasai, Y. Nakamura, T. Yamanaka, H. Okamoto
Journal: Annals of Oncology (2018)
Prognostic Value of Free Testosterone (FT) Levels During Salvage Chemotherapy with Carboplatin Plus Weekly Docetaxel in Metastatic Castration- and Docetaxel-Resistant Prostate Cancer (MDRPC)
Authors: C.W.M. Reuter, M.A. Morgan, M. Fenner, V. Grünwald, A. Ganser
Journal: Annals of Oncology (2012)
P1.16-46 A Population-Based Validation Study of the Proposed ‘R-Factor’ Classification in a Lung Cancer-Endemic Region of the US
Authors: M. Smeltzer, N. Faris, M. Ray, C. Fehnel, O. Akinbobola, C. Houston-Harris, P. Ojeabulu, Y. Lee, E. Owen, R. Eubanks, H. Dox, D. Talton, H. Wiggins, B. Wolf, P. Levy, E. Robbins, R. Osarogiagbon
Journal: Journal of Thoracic Oncology (2018)
P2.16-40 Impact of Preoperative Pectoralis Muscle Quantity and Density on Outcome After Complete Resection of Non-Small Cell Lung Cancer
Authors: C. Sun, M. Anraku, M. Sato, J. Nitadori, K. Nagayama, K. Kitano, T. Karasaki, J. Nakajima
Journal: Journal of Thoracic Oncology (2018)
Patients’ roles in research: where is Africa?
Authors: James Ditai, Andrew Weeks
Journal: BMJ (2018)

Patients’ roles and rights in research are vital.1 In Africa, the challenges are greater than in other parts of the world owing to the large educational and societal gap between researchers and patients. Researchers may study matters affecting patients categorised as “illiterate” or “literate but not emancipated” and whose life experience is atypical. This can lead to well meaning but …
Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors
Authors: B. Glisson, R. Leidner, R.L. Ferris, J. Powderly, N.A. Rizvi, B. Keam, R. Schneider, S. Goel, J.P. Ohr, Y. Zheng, S. Eck, M. Gribbin, D.M. Townsley, V. Chiou, S.P. Patel
Journal: Annals of Oncology (2018)
Detection of frailty in elderly colorectal càncer patients: Is G8 a good screening tool?
Authors: G. Soler, J.C. Ruffinelli Rodriguez, R. Legido, M. Martinez Villacampa, F.J. Perez, B. Pardo-Burdalo, J.A. Marín, I. Morilla Ruiz, L. Heras Lopez, S. Vazquez, S. Recalde, M. Plana Serrahima, C. Santos, N. Mulet Margalef, A. Teule, R. Salazar, M.C. Galan, J. Saldaña
Journal: Annals of Oncology (2018)
P2.03-31 LncRNA RGMB-AS1 Affects Lung Adenocarcinoma Prognosis by Regulating Microtube Associated Genes: A Genome-Wide Analysis in Silicon
Authors: X. Shi, Y. Wang, D. Lu, X. Liu, S. Feng, X. Dong, K. Cai
Journal: Journal of Thoracic Oncology (2018)
P1.13-02 eXalt3: Phase 3 Randomized Study Comparing Ensartinib to Crizotinib in Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer Patients
Authors: L. Horn, Y. Wu, M. Reck, H. Wakelee, C. Liang, K. Harrow, V. Oertel, T. Mok
Journal: Journal of Thoracic Oncology (2018)